Denali Therapeutics Inc. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
Denali Therapeutics Inc. (DNLI) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-26.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2021-08-04
- Denali Therapeutics Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2020-12-31 was $0.00.
- Denali Therapeutics Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2020-09-30 was $0.00.
- Denali Therapeutics Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2020-06-30 was $0.00.
- Denali Therapeutics Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2020 was $0.00.
- Denali Therapeutics Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2019 was -$400.00K.
- Denali Therapeutics Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2018 was $0.00.
- Denali Therapeutics Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2017 was $0.00.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $0.00 derived: sum of 2 quarters · filed 2021-02-26 | $0.00 derived: sum of 3 quarters · filed 2021-08-04 | $0.00 10-K · filed 2021-02-26 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-08-04 | $0.00 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-04 | |||
| 2019-12-31 | -$400.00K 10-K · filed 2020-02-27 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-26 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |